Serina Therapeutics (SER) FCF Margin (2018 - 2025)

Serina Therapeutics has disclosed FCF Margin across 8 years of filings, most recently posting 2920.0% for Q2 2025.

• In Q2 2025, FCF Margin rose 1278392.0% year-over-year to 2920.0%; the TTM figure through Dec 2025 stood at 13891.54% (up 1674953.0% YoY), while the FY2025 annual figure was 13891.54%, up 1674953.0% from the prior year.
• FCF Margin came in at 2920.0% for Q2 2025 at Serina Therapeutics, down from 32814.29% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 32814.29% in Q4 2024 to a low of 32720.0% in Q1 2022.
• Average FCF Margin over 5 years is 9505.92%, with a median of 10096.43% recorded in 2023.
• The largest YoY upside for FCF Margin was 3281263 bps in 2024 against a maximum downside of 2945667 bps in 2024.
• Over 5 years, FCF Margin stood at 7850.0% in 2021, then tumbled by 110 bps to 16512.5% in 2022, then surged by 100 bps to 1.65% in 2023, then surged by 1986129 bps to 32814.29% in 2024, then tumbled by 109 bps to 2920.0% in 2025.
• Per Business Quant data, the three most recent FCF Margin figures were 2920.0% in Q2 2025, 32814.29% in Q4 2024, and 21178.57% in Q3 2024.